India’s pharmaceutical industry, valued at US$ 55 billion in FY 2023-24, is rapidly emerging as a global healthcare powerhouse. With projections to reach US$ 130 billion by 2030 and an aspirational US$ 450 billion by 2047, the sector is set to nearly double its global market share to 5%. Already the world’s largest vaccine producer and a top supplier of generics—fulfilling 20% of global demand—India’s robust pharma export footprint spans over 200 countries. Backed by innovation, cost efficiency, and government support, India’s pharma sector is not just growing—it’s transforming into a cornerstone of global health and a pillar of the nation’s economic future. India’s pharmaceutical industry stands at a critical juncture in its growth trajectory. Valued at approximately US$ 55 billion as of FY 2023-24, the sector is poised for exponential expansion, with projections estimating its value between $120 billion and US$ 130 billion by 2030. This anticipated 2.2 to 2.4 times growth will boost India’s share in the global US$1.6 trillion pharmaceutical market from the current 3–3.5% to nearly 5%. The government’s ambitious goal of becoming a US$30–35 trillion economy by 2047 firmly places pharmaceuticals as a vital contributor to this vision. The Indian pharmaceutical industry, already the world’s third-largest by volume and 14th by value, is known for its resilience, cost efficiency, and scale. It is the fifth-largest contributor to India’s manufacturing Gross Value Added (GVA), generating significant trade surpluses and supporting nearly one million livelihoods. India’s global reputation as the “Pharmacy of the World” is further reinforced by its role as the largest producer of vaccines, supplying around 60% of global vaccine requirements to more than 150 countries. India’s Pharma Exports: Expanding Global Footprint India’s pharmaceutical exports, valued at US$ 26.5 billion in FY 2023-24, outpaced domestic consumption (US$ 23.5 billion), signifying a robust international demand for Indian medicines. These exports are expected to more than double to US$ 65 billion by 2030, and reach an aspirational US$ 350 billion by 2047. As the largest global supplier of generic medicines, India currently fulfills approximately 20% of global generics demand and exports one in every five generic drugs sold worldwide. The United States remains the largest export market, accounting for nearly 40% of India’s pharmaceutical exports. Beyond the US, India’s pharma supply chain spans around 200 countries, including African, European, and Southeast Asian nations. The country supplies nearly 50% of Africa’s requirement for generics and 40% of the US market’s generic needs. Key drivers of export growth include India’s diversification into high-value segments such as biosimilars, vaccines, new chemical entities (NCEs), and new biological entities (NBEs). Reports such as Bain & Company’s Healing the World emphasize the need for further innovation to help India secure a top-five spot globally in terms of pharmaceutical exports value by 2047. India is the third-largest nation in terms of pharma exports by volume Pharmaceutical exports in 2023, approximate figures in thousands of tons *, Source: bain.com Key Players in India’s Pharma Ecosystem India’s pharmaceutical industry is driven by a wide network of over 3,000 companies and more than 10,000 manufacturing units. The country is home to 650+ US FDA-compliant plants, the highest number outside the US, testifying to the quality and compliance of Indian pharmaceutical manufacturing. Key industry players include: Sun Pharmaceutical Industries – The largest pharmaceutical company in India and a global leader in specialty generics. Dr. Reddy’s Laboratories – Renowned for its presence in generics and biosimilars. Cipla – A pioneer in affordable respiratory and antiretroviral therapies. Lupin, Aurobindo Pharma, and Glenmark – Major contributors in the generic, API, and specialty segments. Telangana stands out as a hub of pharmaceutical innovation, hosting over 1,000 pharma and biotech firms valued at $50 billion. With 214+ USFDA-approved facilities and over 20 life sciences incubators, the state is positioning itself as the “Pharmaceutical Hub of the World.” Challenges Faced by the Industry Despite its growth and global standing, India’s pharmaceutical industry faces several challenges: Regulatory Compliance: While Indian firms have made strides in maintaining global quality standards, recurring warnings from regulatory authorities like the US FDA indicate the need for consistent quality control and compliance upgrades. Dependence on Imports for APIs: India imports nearly 65–70% of its Active Pharmaceutical Ingredients (APIs), especially from China. This dependency poses strategic risks and supply chain vulnerabilities. Limited Innovation Pipeline: While Indian companies dominate in generics, progress in developing patented new chemical entities and biologics has been limited due to high R&D costs and longer development timelines. Price Control Policies: Government regulations, such as the Drug Price Control Order (DPCO), aim to keep medicines affordable but often squeeze margins for manufacturers, potentially impacting profitability and R&D investment. Global Competition: With emerging pharma hubs in Southeast Asia and Latin America, India faces increasing competition in both cost and quality, necessitating continuous innovation and upskilling. Opportunities for Future Growth Despite the hurdles, India’s pharmaceutical sector holds immense promise: Innovation and Diversification: With growing investments in R&D, India is expanding its capabilities in complex generics, biosimilars, and cutting-edge biologics. Government schemes like the Production-Linked Incentive (PLI) scheme encourage high-value manufacturing and innovation. Rising Global Healthcare Needs: Ageing populations, rising chronic diseases, and increasing healthcare spending globally present a long-term demand for affordable medicines, which India is well-placed to meet. Robust Infrastructure and Workforce: India’s skilled scientific talent pool, extensive manufacturing base, and cost-effective production capabilities provide a competitive edge. Government Support and FDI: India permits 100% FDI in greenfield pharma ventures and up to 74% through the automatic route in brownfield projects, boosting investor confidence. Public Healthcare Initiatives: Domestically, schemes like the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) have made over 1,965 medicines and 293 surgical products available at affordable rates through 10,000+ Janaushadhi Kendras, expanding access and stimulating demand. India’s pharmaceutical industry stands as a cornerstone of the country’s economic and healthcare ambitions. With a strong foundation in generics, a growing focus on innovation, and active government support, the sector is poised for robust growth. The journey from a $55 billion market to a $450 billion industry by
FSSAI cracks down on fake dairy products: New rules, clear labels
The Food Safety and Standards Authority of India (FSSAI) is seeking public feedback on regulations for dairy analogues, such as paneer, in food products. Key issues include clear labelling, distinguishing analogues from genuine dairy, and ensuring proper ingredient disclosure. The FSSAI also proposes restrictions on the sale of loose dairy analogues, and the need for State and Central licenses for manufacturers. Additionally, FSSAI has launched a digital tool for consumers to report misleading claims on packaged foods, enhancing transparency and consumer protection. Image Source: Pixabay The Food Safety and Standards Authority of India (FSSAI) has invited public comments on the enforcement of regulations concerning the use of dairy analogues including paneer (cottage cheese), in food products. A consultation paper has also been released to facilitate discussions on the matter. This move follows a meeting held at the FSSAI headquarters (New Delhi), which focused on compliance issues regarding dairy analogues—particularly after reports surfaced about such products being misrepresented and sold as genuine dairy items. FSSAI already mandates clear and distinct labelling for dairy analogues to differentiate them from actual dairy products. This issue has gained additional attention after the Minister for Consumer Affairs recently urged the Ministry of Health to take action in response to incidents of fake paneer being sold in various markets. What is dairy “analogue”? As per the Sub-regulation 2.1.1 (1), clause (aa) of Food Safety and Standards (Food Product Standards and Food Additives) Regulations, 2011: A dairy analogue refers to ‘a product in which constituents not derived from milk take the place, in part or in whole, of any milk constituent(s) and the final product resembles, organoleptically and/or functionally, milk or milk product or composite milk product as defined in these regulations’. For instance, analogue paneer, made using ingredients like vegetable oil, starch, and emulsifiers instead of milk, is the most commonly sold dairy analogue in the market. Its sale is not illegal—provided it is clearly labeled as an analogue product. Clear disclosure and labelling is required The Food Safety and Standards Authority of India (FSSAI) has established regulations requiring clear and distinct labelling of ‘Analogue in Dairy Context’ products to differentiate them from genuine dairy items. In light of the growing instances of such products being falsely presented as real dairy, FSSAI has underscored the critical need for clear disclosure and accurate labelling. According to the sub-regulations under the Food Safety and Standards (Food Product Standards and Food Additives) Regulations, 2011, dairy analogues are not recognized as milk, milk products, or composite milk products. Therefore, no label, commercial document, promotional material, or point-of-sale display may claim, imply, or suggest that the product is milk or a milk-based product, or make any reference to such products. Chapter-2, Sub-regulation 4 (3) Food Safety and Standards (Labelling & Display) Regulations, 2020 clearly mentions that- manufacturers must not describe or present pre-packaged food on any label or in any labelling in a way that is false, misleading, deceptive, or likely to create a misleading impression about its nature in any way. Food Safety and Standards (Licensing & Registration of Food Businesses) Regulations, 2011, in other conditions of license (Condition number 2 of Annexure-3 of Schedule 2) mentioned that- hotels, restaurants, and caterers selling cooked food are required to display a notice board that outlines the nature of the items being offered for sale. FSSAI seeks public comments Considering the current regulations and the deliberations with stakeholders, FSSAI has requested stakeholders to provide their responses to the following suggestions, supported by justifications, reasoning, and any relevant documents or examples, if applicable. It is seeking public feedback on: Nomenclature for ‘Analogue in Dairy Context’ on Labels: The terminology used for products referred to as ‘Analogue in dairy context’ should be clearly defined. It is suggested that terms like ‘Non-dairy’ or ‘Analogue’ be used as prefixes to dairy-related terminology. This applies when milk constituents are either partially or wholly substituted. Label Declaration for Pre-Packaged Foods Containing ‘Analogue in Dairy Context’ Ingredients: When ‘Dairy analogue’ is used as an ingredient in pre-packaged food, the nature of the ‘Dairy analogue’ should be clearly stated in the ingredient list (e.g., Analogue of cream, Analogue of cheese, etc.). This should be followed by a list of the ingredient components in descending order of proportion, provided in brackets. For example: Ingredients: Analogue of Cheese (Milk Solids, Refined Palm Oil, Hydrogenated Vegetable Fat, Modified Starch, Emulsifier). Declaration of Nature of Food Items served in the HoReCa Industry: Food service establishments, including restaurants and caterers, that serve cooked or prepared food (either directly or indirectly) containing ‘Dairy Analogue’ as an ingredient should clearly indicate the exact nature of the food items on menu cards, boards, booklets, or other materials. The terms ‘Non-dairy’ or ‘Analogue’ should be used as a prefix before any dairy term, ensuring that consumers are well-informed. For example: If ‘Analogue of Paneer’ is used in Kadhai Paneer or ‘Analogue of Cheese’ is used in a Burger instead of dairy products, the exact nature of the ingredient must be specified to provide consumers with an informed choice. Prohibition n in sale of ‘Analogue in Dairy Context’ in Loose Form: ‘Analogue in dairy context’ products should only be sold in packaged forms weighing no less than 500 grams, with clear labelling declarations as per the regulations outlined under sub-regulation 2.1.1 (5), clause (b) of the Food Safety and Standards (Food Product Standards and Food Additives) Regulations, 2011. Restriction on FSSAI Registration for Dairy Analogue Manufacturers: Currently, petty food manufacturers with a turnover of up to Rs. 12 Lakh per annum or a production capacity of up to 100 Kgs/Ltrs per day are eligible for FSSAI registration. To prevent the potential misuse of dairy analogues as substitutes for actual dairy products, it is suggested that FSSAI registration be restricted for food businesses manufacturing ‘Dairy Analogue’ products (such as Analogue of Paneer, Analogue of Cream, Analogue of Milk, Analogue of Cheese, etc.). The manufacture of ‘Analogue in dairy context’ will only be permitted under State and Central licenses, ensuring better
India’s generics under pressure as US targets global drug prices
U.S. President Trump’s “Most Favoured Nation” (MFN) pricing policy seeks to lower prescription drug costs by ensuring the U.S. pays no more than the lowest price worldwide. This could pressure countries like India, a major producer of affordable generics, to raise drug prices — potentially undermining the global competitiveness of Indian generics as pharmaceutical companies push for higher prices in low-cost markets. India’s pharmaceutical industry, vital for affordable global access, could face increased scrutiny over its intellectual property laws. The policy’s impact may lead to changes in trade negotiations and India’s patent system, with concerns over how it could affect competitiveness and public health globally. Image credit: Freepik Global pharmaceutical companies are expected to increase pressure on India and other developing nations to raise the prices of medicines, following U.S. President Donald Trump’s announcement of a new drug pricing policy. The executive order, which was aimed at curbing the soaring cost of prescription drugs in the United States, introduced a “Most Favoured Nation” (MFN) pricing model. Under this framework, the U.S. would not pay more for a drug than the lowest price paid by any country in the world. Trump argued that the move was long overdue, citing the vast discrepancies in global drug pricing. In a social media post, he stated that Americans often pay five to ten times more for the same medication, produced by the same manufacturer in the same facility, compared to consumers in other countries. The MFN policy, he claimed, would cut prescription drug prices in the U.S. by 30% to 80% almost immediately, marking a significant shift in the pharmaceutical pricing landscape. While the policy promises immediate relief for American patients, international trade experts have warned that it could lead to widespread ripple effects. Specifically, they anticipate a global price recalibration, with multinational drug companies lobbying for higher drug prices in lower-cost regions. India’s generics, known globally for their affordability and scale, are expected to come under intense pressure to raise prices amid shifting global drug pricing policies. The logic is simple: under the MFN rule, low drug prices in India and other similar markets could directly influence prices in the much larger and more profitable U.S. market. India’s pharmaceutical industry concerns India’s pharmaceutical industry plays a crucial role not only domestically but also globally, particularly in supplying affordable generic medications to markets in the U.S., UK, and Africa. This cost advantage, however, has made India a frequent target of criticism from Western pharmaceutical giants, who argue that India’s intellectual property regime undermines innovation and competitiveness. These firms often point to India’s strict criteria for patentability and its resistance to practices like “evergreening,” which extend patent life through minor modifications. Adding fuel to the fire, the United States has placed India on its “Priority Watch List” for intellectual property rights, citing concerns over patent enforcement and regulatory transparency. The US accounts for nearly one-third of India’s pharmaceutical Industry exports, amounting to approximately US$9 billion in the last fiscal year. A wake-up call for India Mr. Ajay Srivastava, head of the Global Trade and Research Initiative (GTRI), sees the MFN move as a ‘wake-up call’ for India. He stated that Western pharmaceutical companies, facing tighter price controls at home, will redouble efforts to extract higher prices in markets like India. He noted, “The battleground is no longer just legal—it has moved to trade negotiations. India must respond with strategic clarity and unyielding resolve. As global pharmaceutical firms turn to free trade agreements (FTAs) to extract Trade-Related Aspects of Intellectual Property Rights ‘(TRIPS)-plus’ commitments, India must hold the line on its patent regime—one that enables affordable access, prevents monopolistic extensions, and safeguards public health.” Mr. Srivastava also noted that pharma prices would now dominate the bilateral trade agreement negotiations. India and the US are set to sign a bilateral trade agreement by September-October this year. “The world depends on India’s generics. Preserving this model is not only in India’s interest, it’s a moral and global necessity,” he said. India’s pharmaceutical Industry laws are currently aligned with the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). However, developed countries have increasingly pushed for India to adopt “TRIPS-plus” provisions through FTAs. These include measures such as data exclusivity, patent linkage, automatic patent term extensions, broader patentability criteria, and evergreening practices. Distributors’ margins could shrink According to a pharma industry executive, the order may not adversely impact Indian generic manufacturers. Instead, the executive believes the pressure will shift to the distribution networks and the manufacturers of patented drugs. The executive noted that of the US$ 670 billion US pharma market, only 21% consists of generics, while the remaining 79% comprises patented medications. In the generics space, price erosion has already taken place. The real issue is the supply chain, which is controlled by a handful of powerful distributors. These entities often keep their profits offshore, which is something the Trump administration should address. He further pointed out that many patented drug manufacturers are headquartered outside the U.S. in countries like Ireland and various parts of Europe. This allows them to benefit from lower corporate taxes while continuing to generate enormous profits from their U.S. operations. The Indian Pharmaceutical Association, however, has yet to officially respond to the executive order, but its previous positions suggest strong concern over policies that could impact the competitiveness and profitability of Indian drug manufacturers. The announcement of the MFN policy had immediate repercussions in financial markets. Concerns over declining profit margins led to a sell-off in pharmaceutical stocks. U.S.-based drug companies saw significant declines in their stock values, and Indian generics stocks also took a hit amid uncertainty over how the new policy might reshape global pricing dynamics.
FMCG eyes recovery in H1FY26, consumer durables to maintain growth
India’s FMCG sector is expected to see a demand rebound in early FY26, supported by a revival in rural consumption and easing inflation, as per a report by ShriRam Mutual Fund. The consumer durables segment also shows growth potential, particularly in premium cooling products. However, rising raw material costs may pose challenges to profit margins. At the same time, equity markets are experiencing heightened volatility due to global trade tensions. India’s fast-moving consumer goods (FMCG) sector is poised to witness a revival in demand in the first half of the financial year 2025-26 (H1FY26), as per a recent report released by ShriRam Mutual Fund. The resurgence is expected to be driven by improving rural consumption trends, a decline in inflationary pressures, and strategic pricing measures undertaken by companies. After a period marked by uneven performance and macroeconomic headwinds, the FMCG segment is gearing up for a more favorable business environment. The report stated, “FMCG is poised for a demand rebound in H1FY26, aided by rural recovery, softening inflation, and supportive pricing.” A key factor supporting the expected recovery is the improvement in rural demand, which had slowed down in previous quarters due to high food inflation and income pressures. However, with inflation now easing and better rainfall forecasts bolstering rural income prospects, consumption in non-urban markets is showing signs of revival. Companies in the FMCG space are also adopting more calibrated pricing strategies, offering value packs and promotional pricing to stimulate demand. These measures, along with stabilizing input costs, are helping restore consumer confidence. Urban demand, which remained relatively steady throughout the downturn, is also expected to gain momentum. Categories like packaged foods, personal care, and beverages are likely to benefit the most from this renewed consumption wave. While the FMCG sector readies itself for a near-term rebound, the consumer durables sector continues to reflect a long-term growth narrative, albeit with some immediate challenges. The ShriRam Mutual Fund report noted that demand for premium products and rising temperatures have boosted sales in categories like fans and cooling appliances, especially in the northern parts of the country. However, not all sub-segments are performing equally. Electrical consumer durables (ECD) and room air conditioners (RACs) are facing hurdles in the form of elevated raw material costs and limited ability to pass on these costs to end consumers. As a result, margins in the RAC segment remain under pressure. The report cautioned, “High raw material costs and limited pricing power may pressure RAC margins.” Additionally, the delay in the onset of summer in southern India temporarily affected the seasonal sales cycle, though demand in northern regions is picking up. The report also touched upon market dynamics affecting the performance of FMCG and consumer durable stocks. Rising global trade tensions, particularly concerns over tariffs imposed by the United States, have led to increased volatility in domestic equity markets. This global uncertainty has spilled over into Indian financial markets, contributing to fluctuations in investor sentiment. Despite these headwinds, both FMCG and consumer durable sectors delivered notable gains over the past month. The Nifty FMCG index rose by 5.33%, while the Nifty Consumer Durables index climbed 4.06%, reflecting optimism around improving demand and relatively stable input costs. However, the medium-term picture appears more measured. Over the last three months, Nifty Consumer Durables gained a modest 1.09%, while Nifty FMCG increased by 1.60%. This tempered growth reflects investor caution, particularly about the pace of rural recovery and the potential impact of macroeconomic risks. Over the six-month period, both indices registered declines — Nifty FMCG fell by 5.53%, and Nifty Consumer Durables declined by 6.30%. These figures suggest that elevated interest rates and inflation may have constrained consumer spending during that timeframe. Looking at the long-term perspective, consumer durables continue to inspire greater investor confidence compared to FMCG. Over the past year, Nifty Consumer Durables posted a 7.13% gain, outpacing the 4.06% rise in Nifty FMCG. This outperformance underscores the durability of India’s aspirational consumption story, supported by rising incomes, urbanization, and greater demand for home appliances and lifestyle products. The ShriRam Mutual Fund report paints a cautiously optimistic picture for India’s consumer-driven sectors. While the FMCG industry is gearing up for a short-term rebound in H1FY26, the consumer durables sector continues to exhibit strong long-term potential despite near-term margin pressures. Both sectors will remain key indicators of India’s consumption resilience amid global uncertainties and evolving domestic dynamics.
Navigating complex trade compliance with AI
From validating certificates of origin to identifying transshipment red flags, artificial intelligence is transforming manual, error-prone customs procedures into smart, adaptive systems. As regulators like the US Customs and Border Protection (CBP) adopt AI-powered surveillance tools, exporters must match pace to maintain access and credibility in key markets. This article explores how cutting-edge AI solutions—from document automation to predictive risk scoring—are helping Indian businesses navigate evolving trade regulations, prevent costly detentions, and build resilient, compliant supply chains in a geopolitically volatile world. The U.S.-China trade war has catalyzed a complex rerouting ecosystem where Indian exporters risk becoming unwitting participants in tariff circumvention schemes. Amid heightened scrutiny from U.S. Customs and Border Protection (CBP) and India’s tightened CAROTAR 2.0 rules, artificial intelligence (AI) emerges as a critical defense mechanism. By automating trade documentation, predicting compliance risks, and profiling supplier networks, AI co-pilots are redefining how exporters navigate this high-stakes landscape while safeguarding India’s trade integrity. Modern trade compliance hinges on accurately processing hundreds of data points across commercial invoices, bills of lading, and certificates of origin. AI systems like iCustoms’ document processing engine and Passage’s validation algorithms automate this workflow through: Optical Character Recognition (OCR) 2.0: Advanced models extract text from scanned documents while cross-referencing fields like harmonized system (HS) codes and invoice values, reducing manual entry errors significantly. Real-Time Discrepancy Flagging: Machine learning compares declared values against historical shipment patterns, instantly alerting exporters to anomalies like sudden spikes in product volumes or mismatched supplier addresses. Dynamic Regulation Updates: Natural language processing (NLP) scans updates from 190+ global customs portals, automatically adjusting documentation requirements for new tariffs or trade embargoes. For Indian solar panel exporters, these tools proved vital when CBP revised origin criteria for photovoltaic cells in Q1 2025. AI systems updated self-certification templates within hours, whereas manual processes typically required 14–21 days. Predictive risk profiling: Anticipating customs red flags Beyond reactive compliance, AI enables proactive risk mitigation through: Supply chain graph analysis Platforms like TradeBeyond’s chain of custody suite map multi-tier supplier relationships, identifying hidden connections to sanctioned entities or embargoed regions. By analyzing procurement patterns and shipping routes, the system flagged a Surat-based textile exporter’s indirect sourcing from Xinjiang cotton farms, preventing a potential US Customs detention under the Uyghur Forced Labor Prevention Act (UFLPA). Behavioral anomaly detection Machine learning models trained on millions of cleared shipments detect subtle red flags: Unusual transshipment patterns: An AI model developed by Servient identified a Gujarat machinery parts supplier whose ASEAN-bound shipments consistently rerouted to U.S. ports—a hallmark of Chinese triangulation schemes. Financial irregularities: Algorithms cross-reference supplier bank statements with export declarations, surfacing discrepancies like under-invoiced raw material purchases from China. Dynamic risk scoring Each consignment receives a risk score (0–100) based on multiple parameters, including: Supplier’s historical compliance rate Geopolitical stability of transit countries Regulatory alignment between origin and destination markets Exporters with high-risk scores trigger mandatory enhanced due diligence, reducing penalty risks substantially. Automated origin verification: Closing the transshipment loophole India’s Common Digital Platform for Certificates of Origin (CoO) now integrates AI validation layers that: Cross-check production records against GST returns to verify value addition claims Analyze factory floor sensor data (IoT) to confirm manufacturing timelines Scrape global shipping databases for parallel shipments of identical goods from Chinese ports A pilot with Maharashtra auto parts exporters demonstrated high accuracy in detecting falsified CoO claims compared to manual audits. AI-enhanced supplier vetting: Building compliant networks Unilever’s AI procurement model, adapted for Indian MSMEs, evaluates suppliers using: Financial health algorithms: Predicting bankruptcy risks by analyzing RBI’s CRILC database and credit bureau reports Sustainability compliance checks: Cross-referencing ESG certifications against global watchlists Geopolitical exposure scores: Mapping supplier facilities to conflict zones using satellite imagery and news sentiment analysis This system helped a Coimbatore precision tools exporter replace 23 Chinese component suppliers with compliant alternatives during the 2025 Taiwan Strait crisis. The road ahead: Integrating AI into India’s trade ecosystem While AI tools offer transformative potential, their effectiveness hinges on: Unified data lakes: Merging DGFT, GSTN, and RBI databases into federated learning systems that improve model accuracy without compromising data sovereignty Regulatory sandboxes: Allowing exporters to test AI compliance solutions against synthetic customs scenarios under ICEGATE supervision Skill development: Partnering with NASSCOM to certify 50,000 trade professionals in AI-assisted compliance by 2026. As CBP deploys its own AI-driven Anti-Circumvention Intelligence Platform (ACIP) in 2025, Indian exporters must adopt equally sophisticated tools to maintain market access. Those leveraging AI’s predictive capabilities will not only avoid penalties but also position India as a reliable alternative to China in reshoring initiatives—a potential $1.2 trillion opportunity by 2030. In the words of a Mumbai-based trade compliance officer: “AI isn’t replacing our expertise—it’s amplifying our ability to spot risks we couldn’t see before.” For India’s export community, this technological partnership may well determine their place in the new global trade order. Authored by : Liquidmind.AI Citations: https://www.icustoms.ai/blogs/automating-trade-compliance-checks-ai-machine-learning/ https://www.linkedin.com/posts/y-combinator_passage-yc-s24-is-the-ai-copilot-for-clearing-activity-7219747756582608897-lGPi https://www.cimphony.ai/insights/what-is-ai-for-customs-streamlining-trade-compliance https://www.wns.com/perspectives/articles/articledetail/1277/how-ai-is-transforming-supplier-risk-management-in-retail-cpg https://www.everstream.ai/articles/artificial-intelligence-role-in-supply-chain-risk-management/ https://customscity.com/the-digital-revolution-in-customs-compliance-how-ai-and-automation-are-transforming-section-321-fda-prior-notice-and-trade-compliance-in-2025/ https://www.docsumo.com/blog/intelligent-document-processing-use-cases https://www.oracle.com/a/ocom/docs/applications/supply-chain-management/oracle-trade-compliance-ds.pdf
India’s plastic credit market set to reach US$1.67 billion by 2030
India’s plastic credit market is expected to grow to US$1.67 billion by 2030, fueled by extended producer responsibility (EPR) regulations that mandate the use of recycled content in plastic packaging. While these policies are accelerating the shift toward circular economy practices, the sector continues to face hurdles such as sourcing high-quality recyclable plastic at viable prices and managing the complexities of reverse logistics. Industry experts stress the urgent need for robust and efficient collection infrastructure to support recyclers and sustain the market’s long-term expansion. Image Credit: Pixabay India’s plastic credit market is poised for exponential growth, potentially reaching a valuation of US$1.67 billion by 2030, up from its current size of US$982 million, according to industry experts. This surge is being driven by a regulatory push under the Extended Producer Responsibility (EPR) framework, which mandates that plastic producers, importers, and brand owners use recycled content in their plastic packaging. The plastic credit mechanism functions similarly to carbon credits. Companies can trade plastic credits — units that represent the verified collection and recycling of plastic waste — to meet their compliance obligations or sustainability goals. This market-based approach incentivizes recycling and builds accountability across the plastic value chain. The use of recycled content in plastic packaging became a regulatory requirement from April 1, 2025. Under the EPR rules, companies are now obligated to incorporate 5% to 30% recycled plastic in their packaging in the first year, depending on the category of plastic used. This requirement will gradually increase to between 10% and 60% by the financial year 2028-29. Industry insiders see the mandate as a much-needed boost to the recycling ecosystem. “It’s a big positive; the mandate has expanded the market for recyclers, incentivising industry to thrive,” said Rashi Agrawal, Chief Business Officer at Banyan Nation, a Hyderabad-based plastics recycling firm. However, the growth of the plastic credit market isn’t without its hurdles. Key challenges revolve around the logistics of collecting plastic waste, procurement of recyclable material at scale, and establishing an effective price discovery mechanism for credits. One major issue is reverse logistics — the process of collecting used plastics from consumers and transporting them to recycling facilities. It will be necessary to develop mechanisms so that plastics are collected efficiently from households and other sources, while managing the additional costs. Besides this, recyclers also face procurement bottlenecks. The price discovery mechanism for plastic credits is another area that needs attention. As more organizations enter the plastic credit trading space, the market must develop transparent systems to determine fair pricing for credits, which can vary based on the type, volume, and origin of plastic waste recycled. Despite these operational and infrastructural challenges, stakeholders are optimistic that the plastic credit market will play a crucial role in accelerating India’s transition to a circular economy. The rising demand for recycled content, fueled by regulatory pressure and increasing environmental consciousness among consumers and corporates, is likely to drive investments in collection infrastructure, recycling technologies, and digital tracking platforms. To sustain this momentum, experts call for greater collaboration between government bodies, industry players, and waste management enterprises. Stronger public-private partnerships, better data management, and technological innovations such as traceability tools and AI-driven waste sorting systems could help streamline operations and reduce inefficiencies. As India confronts its mounting plastic waste crisis, the plastic credit market is emerging as a vital solution — not only for meeting compliance targets under the EPR framework but also for building a more resilient and sustainable recycling ecosystem. If the challenges around logistics, procurement, and pricing are addressed effectively, the sector could become a cornerstone of India’s broader climate and sustainability ambitions.
Egypt’s rising role in global F&B
Egypt’s food and beverage market is undergoing strong growth, reaching US$ 89.5 billion in 2024 and projected to hit US$ 125.4 billion by 2028. Key drivers include urbanization, changing consumer preferences, rising exports, and increased manufacturing. Imports of key items like wheat and processed foods are growing, while local production expands. F&B sector in Egypt includes over 27,000 companies and employs 7 million people. E-commerce, food delivery, and demand for ready-to-eat, high-value products are rising. Egypt’s food and beverage market is experiencing significant growth and transformation, driven by urbanization, evolving consumer preferences, rising domestic consumption, increased exports, and substantial investments in manufacturing and foodservice sectors. In 2024, Egypt’s food market expanded by 35%, reaching Egyptian Pound (EGP) 4.0 trillion (approx US$ 89.5 billion). This growth trajectory is expected to continue, with food spending projected to increase at an average annual rate of 16.8%, reaching US$ 125.4 billion by 2028. Egypt’s food sector exports exceeded US$ 10 billion in 2024, reflecting a 21% year-over-year growth. Egyptian Food Industry- an overview Egypt is the most populous nation in the Arab world and ranks third in Africa, following Nigeria and Ethiopia. In 2023, Egypt’s population was estimated at 109.5 million (CIA World Factbook). With much of the country covered by desert, around 95% of the population lives along the narrow, fertile Nile River valley, which makes up just 5% of Egypt’s total land area. Rapid population growth—an increase of 46% between 1994 and 2014—continues to strain the country’s limited natural resources, as well as its infrastructure for jobs, housing, sanitation, education, and healthcare. As per the Federation of Egyptian Industries’ (FEI) food division, as of 2024, there are 27k member companies, up from just 14k companies in 2020. Of these companies, approximately 1.5k are exporters, contributing about 14% of Egypt’s total non-oil exports and placing the food sector as the country’s third most export-oriented industry. The sector employs over 7 mn workers directly and indirectly. The government aims to increase the food sector’s revenues to over US$ 20 bn by 2030, up from an estimated US$ 7 bn in 2025. Expenditures on basic goods such as bread and oils are expected to rise, while consumer preferences in major cities like Cairo and Alexandria are increasingly leaning towards ready-to-eat and packaged foods. Egypt is the most cost-competitive choice in the region’s food sector, driven by low labor and energy costs. Many global food companies from Europe, Turkey, and across the Middle East already operate manufacturing and export facilities in Egypt—a trend expected to expand as more firms recognize Egypt’s strategic location and competitive advantages as a regional hub. Despite the vast opportunities, Egyptian market faces challenges such as inflation and economic fluctuations, which impact consumer spending behaviours. A heavy reliance on imported goods is contributing to price increases. Euromonitor reports that retail sales of packaged food in Egypt reached US$ 12.7 billion in 2023, an increase of 87.7% or US$ 5.9 billion since 2019. The market is projected to grow further, reaching US$ 23.6 billion by 2028, a rise of 35.6%. As one of the world’s largest grain importers, Egypt’s feed and food industry drives demand for wheat and corn. Edible Oils, Sweet Spreads, Rice, Pasta, and Noodles, Ready Meals, Savory Snacks, are among the other High growth products. Food and beverage imports of Egypt Egypt’s food and beverage imports have experienced notable shifts in 2024, influenced by strategic stockpiling efforts, economic challenges, and policy adjustments. Here’s an overview of the latest data and developments: As one of the world’s largest wheat importers, Egypt depends on the grain to produce subsidized bread that supports tens of millions of its citizens. Its imports of wheat increased by 40% year-on-year (YoY) to 14 million tons during 2024. In comparison, Egypt imported approximately 10 million tons of wheat in 2023. Sources attributed the increase to a rise in private-sector purchases, reflecting efforts to boost local strategic reserves in response to growing domestic consumption. According to data, Egypt’s wheat consumption in MY 2024/25 was at 20.65 MMT, slightly up from the MY 2023/24 estimate of 20.6 MMT. In Marketing Year (MY) 2024/25, Egypt’s total wheat supply is projected to reach 23.7 million metric tons (MMT), with 81.5% designated for human consumption. Key processed food imports of Egypt include: Processed/Prepared Dairy Products Food Preparations and Ingredients Fats and Oils Processed Vegetables and Pulses Chocolate and Confectionery Condiments, Sauces, Jams and Jellies Syrups and Sweeteners Table: Egypt’s main food imports and their leading global suppliers (Jan.–Nov. 2024) Category Total Import Value (USD) Top Suppliers (%) Beef and Beef Products US$995 million 1. India (57%) 2. Brazil (27%) 3. USA (11%) 4. Australia (1.2%) Dairy Products US$741 million 1. New Zealand (22%) 2. Germany (12%) 3. France (9%) 4. USA (6%) Tea US$244 million 1. Kenya (90%) 2. UAE (3%) 3. Sri Lanka (2.2%) 4. India (2%) 5. USA (0.02%) Soup and Food Preparations US$244 million 1. Ireland (26%) 2. Germany (9.3%) 3. Saudi Arabia (9%) 4. Netherlands (5%) 5. USA (3%) Fresh Fruits US$215 million 1. Lebanon (27%) 2. Poland (20%) 3. Greece (19%) 4. Italy (16%) USA (0%) Chocolate and Cocoa US$166 million 1. Malaysia (14%) 2. Netherlands (13%) 3. Spain (12%) 4. Cote d’Ivoire (11%) USA (0.02%) Tree Nuts US$97 million 1. Vietnam (25%) 2. USA (21%) 3. Turkey (11%) 4. Spain (10%) Spices US$95 million 1. Vietnam (27%) 2. China (12%) 3. Guatemala (12%) 4. Brazil (11%) Fresh Vegetables US$75 million 1. UK (32%) 2. Netherlands (29%) 3. France (13%) 4. Denmark (9%) Poultry Meat and Products US$56 million 1. Brazil (98%) 2. Turkey (1.03%) 3. Malaysia (0.06%) Source: Trade Data Monitor Overall Egypt imported roughly US$3.4 billion of consumer food products in 2024. Euromonitor International reports that full-service restaurants saw solid growth in both revenue and new openings in 2023. Despite economic pressures, the appetite for dining out remained strong. The continued growth of Egypt’s tourism sector is also expected to boost demand for food products, especially as it caters to international visitors. India’s food
Agentic AI: Redefining enterprise software pricing and reshaping business models
Agentic AI is revolutionizing pricing models in Indian SaaS and enterprise software by replacing human users with AI-driven bots. This shift is moving companies away from traditional per-user billing towards more dynamic, consumption- and outcome-based models, including API and AI-unit pricing. While AI services now often come with premium pricing, there is growing demand for pricing predictability, leading to the rise of hybrid and bundled service offerings. Emerging trends like value-based subscriptions, shared value partnerships, tokenized services, predictive pricing, and industry-specific models offer greater flexibility, align costs with outcomes, and foster innovation, ultimately enhancing customer trust. Agentic artificial intelligence is reshaping the business models of Indian SaaS and enterprise software companies, as firms increasingly replace human users with AI-driven bots. This shift is prompting a move from traditional per-user pricing to more dynamic models such as consumption- and outcome-based billing. In this evolution, some companies are charging a premium for advanced AI products, while others are adopting API-based billing, where customers pay based on actual usage. Bundled service offerings that integrate AI with other solutions are also gaining traction. Mr. Girish Mathrubootham, founder and executive chairman of Freshworks, explained that businesses previously paid software fees based on the number of users—such as $50 per person for a 100-member team. Now, AI agents can autonomously handle tasks, reducing the need for large teams and lowering user-based licensing costs. The Lifecycle management firms have noted a shift in pricing models to focus on the number of agents and workflows instead of user counts. According to Shobhit Jain, managing director at Avendus Capital, nearly 40–50% of enterprise software operations have transitioned away from the per-user, per-transaction model. Companies are increasingly adopting output-based pricing, where fees depend on the outcomes delivered. Additionally, some firms are introducing distinct pricing models for GenAI services to capture the growing demand. What is Agentic artificial intelligence? Agentic artificial intelligence (AI)—autonomous systems capable of perceiving, reasoning, and acting without constant human oversight—is profoundly transforming the business models of Indian SaaS and enterprise software companies. This shift is not merely about integrating AI features; it’s about reimagining software delivery, customer engagement, and value creation. Traditionally, Indian SaaS companies offered tools that required user intervention. Now, they’re evolving into platforms with embedded AI agents that can autonomously execute tasks. For instance, Gupshup has introduced a library of 15 customizable AI agents, enabling clients like Lenskart and Cars24 to automate customer interactions with sophisticated reasoning and decision-making capabilities. Similarly, Zoho’s Zia Agents and Zia Agent Studio empower businesses to create autonomous agents tailored to their workflows, enhancing operational efficiency. Zomato’s launch of Nugget, an AI-native customer support platform, exemplifies this trend, claiming to resolve up to 80% of queries autonomously . The integration of agentic AI is prompting a shift from traditional subscription models to outcome-based pricing. Platforms like KOGO AI offer an ‘AI agent marketplace’ with over 100 agents, allowing businesses to pay based on usage or specific outcomes . This model provides flexibility and aligns costs with value delivered, although it introduces challenges in cost predictability. Key Emerging Pricing Models 1. Outcome-Linked Pricing Outcome-linked pricing aligns an AI vendor’s compensation with tangible, measurable results—such as cost savings, improved efficiency, or increased revenue. Rather than charging based on software usage or availability, vendors earn based on the actual value delivered. How It Works: The customer and vendor agree upfront on clear performance metrics—like cost reductions, productivity gains, or revenue uplift. The vendor’s fee is then calculated as a percentage of the value generated or as a fixed amount tied to the outcomes achieved. Example: If a procurement AI helps a company save $1 million by optimizing supplier contracts, the vendor might charge 10% of the savings—earning $100,000. Best Suited For: Cost-saving initiatives such as fraud detection, risk reduction, or supply chain optimization. Revenue-generating efforts including marketing performance, sales enablement, or personalized e-commerce experiences. Key Challenges Attribution: Determining how much of the outcome is directly due to the AI solution versus other contributing factors. Variability: Market changes or external events can influence results, making consistent value delivery—and pricing—more complex. 2. Dynamic Performance Pricing Dynamic performance pricing adjusts fees based on how actively the AI system is used and the volume of value-driving actions it performs. As AI activity increases, so does the vendor’s compensation. How It Works: Pricing is linked to operational metrics such as the number of tasks executed, data processed, or AI-driven decisions made. Higher usage or impact results in higher fees. Example: A supply chain AI may incur higher charges during peak periods, such as holidays, when it performs more real-time optimizations to manage demand. Best Suited For: Industries with seasonal or variable demand—like e-commerce during holiday spikes or logistics in high-volume shipping windows. Key Challenges: Cost Predictability: Customers may push back on rising costs during peak times, especially when budgets are already under pressure. 3. Hybrid Pricing Models: A Mix of Stability and Performance Hybrid pricing combines a fixed subscription fee for basic services with variable fees based on performance or results. How It Works: Customers pay a predictable base fee for access to the system, along with additional charges based on specific performance metrics or outcomes. Example An AI HR platform charges a monthly fee for its core features and an extra fee for each successful hire made through its recommendation engine. Best Fit This model suits businesses that want cost predictability while still capturing value from high-impact outcomes. Challenges Hybrid contracts can be complex, requiring careful negotiation to balance fixed and variable pricing components. Future Trends in AI Pricing: The Road Ahead As agentic AI evolves, pricing models are expected to shift to align more closely with delivered value, creating greater flexibility and trust. Key emerging trends include: Value-Based Subscriptions: The AI Fitness Plan Future subscription models will integrate performance metrics, allowing fees to adjust based on outcomes. For instance, a CRM AI could charge based on the retention boost it delivers, offering rebates if targets aren’t met. This aligns vendor incentives with customer goals,
EV shift reshapes auto components industry
The rise of electric vehicles is transforming the auto component industry by increasing content per vehicle and creating new opportunities for suppliers, especially in EV-specific parts like batteries and controllers. However, the shift also poses risks to manufacturers reliant on ICE components and faces challenges such as import dependency and global market pressures. Image Source: Pixabay The transition to electric vehicles (EVs) is set to significantly transform the auto component industry by increasing the content per vehicle and offering new growth opportunities for suppliers, according to a recent report by Ambit Capital. The report noted that while this shift presents a clear threat to manufacturers relying heavily on internal combustion engine (ICE) components, it also brings notable prospects. “While EV disruption poses existential risk for the suppliers of ICE-dependent components, it opens up several opportunities for the component suppliers to provide a) EV components like li-ion batteries, traction motors, controllers, BMS etc,” the report stated. It added that component makers have the potential to diversify into EV-focused parts such as lithium-ion batteries, traction motors, controllers, and battery management systems (BMS). Beyond core EV parts, the rise of electric mobility is also pushing forward the adoption of sophisticated technologies such as regenerative braking, advanced driver-assistance systems (ADAS), and smart cockpit solutions. These advancements are expected to enhance the strategic role of component suppliers within the automotive value chain. Another area of opportunity lies in the growing demand for specific components driven by EV architecture. Parts like wiring harnesses, electronic control units (ECUs), and differential assemblies are projected to see a rise in content per vehicle compared to conventional ICE models. In terms of market outlook, EV penetration in India is anticipated to rise steadily over the next few years. The electric two-wheeler (2W) segment is expected to grow from 6.3% in FY25 to 21% by FY29. Similarly, electric passenger vehicles (PVs) are projected to increase from 2.6% to 10.4% during the same period. The most rapid adoption is forecasted in the electric three-wheeler (3W) segment, which is estimated to surge from 22.9% in FY25 to nearly 68% by FY29. However, the report also sounded a note of caution. It emphasized that a significant portion of EV components is still being imported, which could result in intense competition in the early stages of this transition. This reliance on imports may challenge local suppliers as they try to establish their presence in the EV ecosystem. Despite the promising outlook, the EV shift poses critical risks for certain suppliers. Those whose business models are heavily dependent on ICE engines and select transmission components may face existential challenges if they fail to adapt. In addition to domestic challenges, global headwinds could affect the Indian auto components industry. The report highlighted three external risks: the US-Mexico-Canada Agreement (USMCA)/tariff regime, economic slowdown in the European Union, and increasing competition from Chinese manufacturers. As Indian component suppliers rely significantly on exports to the US and EU, these factors could put pressure on their financial performance in the near future.
India’s wind sector vows to reach 100 gw capacity by 2030
India’s wind energy sector is advancing toward its 2030 target of 100 GW by expanding capacity, innovating technology, and developing its workforce. With over 50 GW already installed, the industry supports the government’s clean energy goals and is poised to boost manufacturing, create jobs, and emerge as a global export hub. India’s wind energy sector is making significant strides toward achieving the national target of 100 GW installed capacity by 2030, according to the Indian Wind Turbine Manufacturers Association (IWTMA). India’s wind energy capacity has crossed 50 GW, as reported by the Central Electricity Authority in its March 2025 update. Mr Aditya Pyasi, CEO, Indian Wind Turbine Manufacturers Association (IWTMA) stated, “The Indian wind industry is fully aligned with the government’s clean energy vision. We are investing in capacity, technology innovation, and workforce development to achieve 100 GW of wind energy by 2030.” During a recent meeting with the Ministry of New and Renewable Energy (MNRE), IWTMA highlighted the sector’s readiness to scale up production, support the ‘Make in India’ initiative, and drive job creation. The wind energy sector is expected to be a major source of employment. In FY25, hiring in the renewable energy space is projected to grow by 19%, with wind power playing a central role. Thousands of jobs are being created in manufacturing, installation, operations, and maintenance. Additionally, over 55% of the sector’s workforce is between 26 and 35 years old, indicating strong appeal among younger generations. Leading companies such as Suzlon, Vestas, Siemens Gamesa, GE Vernova, and Inox Wind are manufacturing critical components—including blades, nacelles, gearboxes, generators, and towers—within India. This well-established value chain supports both national energy needs and positions India as a potential global hub for wind equipment exports. Wind power is crucial for grid stability, complementing solar energy by generating electricity during non-solar hours and helping ensure reliable, affordable, and clean energy around the clock. IWTMA underscored the need for continued government support through stable policies, regulatory reforms, and enhanced infrastructure and testing facilities.
